US payers have a number of mechanisms in their policy toolbox that they can use to steer drug use toward the wave of biosimilars coming on the market – most importantly, prior authorization and requiring that patients try a biologic copy before a branded drug.
As the US has trailed behind Europe in developing a system for approving biologic copies, not to mention lawsuits that have delayed rollouts, biosimilars pricing strategy is still unfolding and payers are still developing their management policies, notes the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?